Cancer Letters
Volume 286, Issue 1 , Pages 52-59 , 1 December 2009

Hepatitis B virus induced hepatocellular carcinoma

Received 2 July 2008 ,Revised 21 November 2008 ,Accepted 2 December 2008.

References 

  1. I.J. Su, H.C. Wang, H.C. Wu, W.Y. Huang, Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection, J. Gastroenterol. Hepatol. (in press).
  2. Soussan P, Garreau F, Zylberberg A, Ferray C, Brechot C, Kremsdorf D. In vivo expression of a new hepatitis B virus protein encoded by a spliced RNA. J. Clin. Invest. 2000;105:55–60
  3. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans IARC Monograph, vol. 59, Hepatitis viruses, WHO press.
  4. Koike K, Shimotouno K, Okada S, Okamoto H, Hayashi N, Ueda K, et al. Survey of hepatitis B virus co-infection in hepatitis C virus-infected patients suffering from chronic hepatitis and hepatocellular carcinoma in Japan. Jpn. J. Cancer Res. 1999;90:1270–1272
  5. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102–110
  6. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Stanzione M, Filippini P, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J. Med. Virol. 2001;65:681–687
  7. Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–1330
  8. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. J. Med. Virol. 2007;79(8):1075–1081
  9. Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, et al. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol. Res. 2008;38:546–556
  10. Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59–68
  11. Takeuchi M, Okamoto E, Fujimoto J. Detection of HBV-DNA from hepatocellular carcinoma by polymerase chain reaction. Nippon Rinsho. 1995;53:718–722
  12. Kobayashi S, Saigoh K, Urashima T, Asano T, Isono K. Detection of hepatitis B virus x transcripts in human hepatocellular carcinoma tissues. J. Surg. Res. 1997;73:97–100
  13. Urashima T, Saigo K, Kobayashi S, Imaseki H, Matsubara H, Koide Y, et al. Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J. Hepatol. 1997;26:771–778
  14. Shintani Y, Yotsuyanagi H, Moriya K, Fujie H, Tsutsumi T, Takayama T, et al. The significance of hepatitis B virus DNA detected in hepatocellular carcinoma of patients with hepatitis C. Cancer. 2000;88:2478–2486
  15. Sheu JC. Molecular mechanism of hepatocarcinogenesis. J. Gastroenterol. Hepatol. 1997;12:S309–S313Review
  16. Grethe S, Heckel JO, Rietschel W, Hufert FT. Molecular epidemiology of hepatitis B virus variants in nonhuman primates. J. Virol. 2000;74:5377–5381
  17. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J. Gen. Virol. 2002;83:1267–1280
  18. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J. Virol. 1991;65:2381–2392
  19. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J. Gen. Virol. 2002;83:2059–2073
  20. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis. 2006;27:2070–2082
  21. Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan CE, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J. Infect. Dis. 2007;195:5–11
  22. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. Proc. Biol. Sci. 1993;253:197–201
  23. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 2005;5:215–229
  24. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004;11:97–107Review
  25. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. New Engl. J. Med. 2004;11:1118–1129
  26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet. 2001;357:539–545Review
  27. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007;39:44–84Review
  28. Safadi R, Friedman SL. Hepatic fibrosis-role of hepatic stellate cell activation. Med. Gen. Med. 2002;27:
  29. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50Review
  30. Villa E, Grottola A, Buttafoco P, Trande P, Merighi A, Fratti N, et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig. Dis. Sci. 1995;40:8–13
  31. Berasain C, Betes M, Panizo A, Ruiz J, Herrero JI, Civeira MP, et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut. 2000;47:429–435
  32. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J. Hepatol. 2001;34:447–454
  33. Borzio M, Trerè D, Borzio F, Ferrari AR, Bruno S, Roncalli M, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol. Pathol. 1998;51:96–101
  34. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 2006;25:3823–3833Review
  35. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J. Hepatol. 2005;42:760–777Review
  36. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res. 2001;1(61):7803–7810
  37. Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995;21:313–321
  38. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 2002;21:525–535
  39. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 2007;8:519–529Review
  40. He B. Viruses, endoplasmic reticulam stress, and interferon responses. Cell Death Differ. 2006;13:393–403(Review)
  41. Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol. Cell. 2004;15:767–776
  42. Travers KJ, Patil CK, Wodicka L, Lockhart DJ, Weissman JS, Walter P. Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell. 2000;101:249–258
  43. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J. Cell Biol. 2004;164:341–346Review
  44. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007;39:44–84
  45. Deodhar KP, Tapp E, Scheuer PJ. Orcein staining of hepatitis B antigen in paraffin sections of liver biopsies. J. Clin. Pathol. 1975;1:66–70
  46. Winckler K, Junge U, Creutzfeldt W. Ground-glass hepatocytes in unselected liver biopsies. ultrastructure and relationship to hepatitis B surface antigen. Scand J. Gastroenterol. 1976;11:167–170
  47. Amat D, Camilleri JP, Feldmann G, Bloch F, Duboust A, Bedrossian J. Hepatocyte localization of hepatitis B core and surface antigens in renal transplant recipients. An ultrastructural prospective study. Virchows Arch. A Pathol. Anat. Histol. 1981;391:153–163
  48. Huang ZM, Yen TS. Dysregulated surface gene expression from disrupted hepatitis B virus genomes. J. Virol. 1993;67:7032–7040
  49. Xu Z, Yen TS. Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J. Virol. 1996;70:133–140
  50. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis. 2004;25:2023–2032
  51. Filippi P, Buras J, McLachlan A, Chisari FV. Overproduction of the hepatitis B virus large envelope polypeptide causes filament storage, ground glass hepatocyte formation, hepatocellular injury an nodular hyperplasia in transgenic mice. In:  Zuckerman AJ editors. Viral Hepatitis and Liver Disease. Alan R Liss Inc.; 1988;p. 632–640
  52. Chemin I, Ohgaki H, Chisari FV, Wild CP. Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver. 1999;19:81–87
  53. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, et al. Extensive oxidative DNA damage, in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 1994;91:12808–12812
  54. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J. Virol. 2004;78:12725–12734
  55. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc. Natl. Acad. Sci. USA. 2004;101:638–640
  56. Zhu Y, Cullen JM, Aldrich CE, Saputelli J, Miller D, Seeger C, et al. Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology. 2004;327:26–40
  57. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN. REVEAL-HBV study group, risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  58. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 2005;97:265–272
  59. Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther. 2006;11:669–679

PII: S0304-3835(08)00933-6

doi: 10.1016/j.canlet.2008.12.003

Cancer Letters
Volume 286, Issue 1 , Pages 52-59 , 1 December 2009

Article Tools

* Image Usage & Resolution